TDC
INSY

Thompson Davis & Co’s Insys Therapeutics, Inc. INSY Stock Holding History

Thompson Davis & Co’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-500
Closed -$10K – 1316
2014
Q3 		$10K Buy
+500
New +$7.85K 0.01% 714

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Thompson Davis & Co's INSY Position: Q4 2014 in Review

Thompson Davis & Co sold out of Insys Therapeutics, Inc. (INSY) in Q4 2014, closing a stake of 500 shares — an estimated $10K sold.

Thompson Davis & Co first reported a position in INSY in Q3 2014 and held it in 1 quarter. The position peaked at $10K in Q3 2014. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2014.

  • Thompson Davis & Co reported no remaining Insys Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 500 Insys Therapeutics, Inc. shares in Q4 2014, an estimated $10K.
  • Thompson Davis & Co first reported a position in Insys Therapeutics, Inc. in Q3 2014 and held it in 1 quarter.
  • Thompson Davis & Co's Insys Therapeutics, Inc. position peaked at $10K in Q3 2014.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2014.

Based on Thompson Davis & Co's 13F filing for Q4 2014, filed 6 Feb 2015.